COLL CRESPO, Blas,ANDRESS, Dennis,BRENNAN, Peter, J.,STOLZENBACH, James, C.
申请号：
HK16110230.1
公开号：
HK1221916A
申请日:
2016.08.29
申请国别(地区):
HK
年份:
2017
代理人:
摘要：
The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol.
